サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1452589

北米のグリオーマ治療：2030年までの市場予測 - 地域別分析 - 疾患別、治療タイプ別、グレード別、エンドユーザー別

North America Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User
出版日: | 発行: The Insight Partners | ページ情報: 英文 92 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
北米のグリオーマ治療：2030年までの市場予測 - 地域別分析 - 疾患別、治療タイプ別、グレード別、エンドユーザー別
出版日: 2024年01月15日
発行: The Insight Partners
ページ情報: 英文 92 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米のグリオーマ治療市場は、2022年の21億7,988万米ドルから2030年には43億7,738万米ドルに成長すると予測されています。2022年から2030年までのCAGRは9.1%と推定されます。

患者に治療へのアクセスを提供する地域・州政府の取り組みが北米のグリオーマ治療市場を後押し

2021年12月、患者アクセスネットワーク（PAN）財団と米国脳腫瘍協会は、膠芽腫患者に対して年間最大1,600米ドル相当のサービスに対する財政支援を提供することで、膠芽腫患者を支援する新たなパートナーシップを発表しました。さらに、北米のグリオーマ治療市場の主要企業は、新製品の上市と既存製品の開発に注力しています。2020年12月、CNSファーマシューティカルズ社は、多形性神経膠芽腫患者の治療薬としてベルビシンの使用が食品医薬品局（Food and Medication Administration）により承認されたことを発表しました。また、食品医薬品局は2021年8月にランタンファーマ社のLP-184を多形膠芽腫およびその他の悪性神経膠腫の治療薬としてオーファンドラッグに指定しました。また、2020年5月には、多形性膠芽腫（GBM）とランタンファーマ社のLP-184のGBMおよび他のタイプの脳腫瘍の治療の可能性に関するウェビナーが開催されました。このように、患者に新規治療へのアクセスを提供するための地域および州政府による取り組みが、北米のグリオーマ治療市場の成長を加速させています。

北米のグリオーマ治療市場概要

北米のグリオーマ治療市場は、米国、カナダ、メキシコに区分され、この地域では米国が最大シェアを占めています。市場成長の主な要因は、脳腫瘍患者の増加、急速な技術革新、ヘルスケアインフラの開拓です。全米脳腫瘍協会が2023年に発表した報告書によると、膠芽腫は最も致命的で複雑な治療抵抗性のがんのひとつです。2023年には14,490人以上の米国人がGBMの診断を受けると予測されており、原発性悪性脳腫瘍全体の～50.1％を占める。北米市場の有力企業は、地理的プレゼンスを拡大し、製品ラインアップを充実させるため、合併、買収、提携、新製品の発売など、さまざまな成長戦略に注力しています。例えば、スウェーデンに本社を置くElekta社は、放射線腫瘍学の分野でイノベーションをもたらすためにGEヘルスケアと提携しました。この提携により、病院は放射線治療を必要とするがん患者に幅広い治療を提供できるようになります。

北米のグリオーマ治療市場では、米国が大きなシェアを占めています。この国の市場成長は主に、脳腫瘍の有病率の増加、グリオーマ治療における技術進歩の拡大、喫煙者の増加によってもたらされます。米国臨床腫瘍学会（ASCO）によると、2022年には米国で約24,530人の成人（男性13,840人、女性10,690人）が脳および脊髄の原発性がん腫瘍と診断されると推定されています。脳腫瘍は中枢神経系（CNS）の原発性悪性腫瘍であり、原発性CNS症例の85～90％を占める。脳腫瘍症例の増加に伴い、より迅速な治療への需要が高まっています。カナダ脳腫瘍登録によると、カナダでは10万人のうち4人が膠芽腫に罹患しており、毎年約1,000人のカナダ人が膠芽腫と診断されています。膠芽腫治療市場のプレーヤーは、カナダ市場で成功するために様々な有機的・無機的戦略を採用しています。2021年2月、メデクサス・ファーマシューティカルズ・インクは、これまでカナダ保健省の特別アクセスプログラムでのみ流通していたグレオランのカナダでの商業的発売を開始しました。グレオランは、高悪性度神経膠腫（悪性で急速に進行する脳腫瘍）を青色光下で蛍光発光させる画像診断薬であり、神経外科医がこれらの神経膠腫をよりよく可視化し、完全に除去するのに役立ちます。現在カナダでは、神経膠腫の手術中に悪性組織を可視化するために承認された光イメージング剤は他にないです。さらに、医療インフラの開拓、研究開発への投資の増加、治療手順の改善が、予測期間中にメキシコの北米のグリオーマ治療市場を牽引すると予測されています。

北米のグリオーマ治療市場の収益と2030年までの予測（金額）

北米のグリオーマ治療市場のセグメンテーション

北米のグリオーマ治療市場は、疾患、治療タイプ、グレード、エンドユーザー、国に区分されます。

疾患に基づき、北米のグリオーマ治療市場は星細胞腫、乏突起星細胞腫、乏突起膠腫にセグメント化されます。2022年の北米のグリオーマ治療市場で最大のシェアを占めたのは星細胞腫セグメントでした。

治療タイプに基づき、北米のグリオーマ治療市場は手術、化学療法、放射線療法、その他に区分されます。2022年の北米のグリオーマ治療市場で最大のシェアを占めたのは手術セグメントでした。

悪性度に基づき、北米のグリオーマ治療市場は低悪性度と高悪性度に区分されます。2022年の北米のグリオーマ治療市場では、高悪性度セグメントが大きなシェアを占めています。

エンドユーザー別では、北米のグリオーマ治療市場は病院＆クリニックと外来手術センターに区分されます。2022年の北米のグリオーマ治療市場では、病院＆クリニック市場が大きなシェアを占めています。

国別では、北米のグリオーマ治療市場はドイツ、米国、カナダ、メキシコに区分されます。米国は2022年に北米のグリオーマ治療市場を独占しました。

Amgen Inc、Amneal Pharmaceuticals Inc、Arbor Pharmaceuticals LLC、Biocon Ltd、F. Hoffmann-La Roche Ltd、Karyopharm Therapeutics Inc、Merck &Co Inc、Pfizer Inc、Sun Pharmaceutical Industries Ltd、Teva Pharmaceutical Industries Ltdは、北米のグリオーマ治療市場で事業を展開する大手企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米のグリオーマ治療市場- 主要産業力学

  • 市場促進要因
    • 患者が治療を受けられるようにするための地域および州政府の取り組み
    • 高悪性度神経膠腫の有病率の増加
  • 主な市場抑制要因
    • 診断コストの高さ
  • 主な市場機会
    • ヘルスケア分野における進歩
  • 今後の動向
    • グリオーマ治療薬の承認急増
  • 影響分析

第5章 グリオーマ治療市場：北米市場分析

  • 北米のグリオーマ治療市場収益、2022年～2030年

第6章 北米のグリオーマ治療市場：収益と2030年までの予測 - 疾患別

  • 市場収益シェア（%）、2022年および2030年
  • 星細胞腫
  • 乏突起星細胞腫
  • 乏突起膠腫

第7章 北米のグリオーマ治療市場：収益と2030年までの予測 - 治療タイプ別

  • 市場収益シェア（%）、2022年および2030年
  • 外科療法
  • 化学療法
  • 放射線療法
  • その他

第8章 北米のグリオーマ治療市場：収益と2030年までの予測 - グレード別

  • 市場収益シェア（%）、2022年および2030年
  • 低悪性度
  • 高悪性度

第9章 北米のグリオーマ治療市場：収益と2030年までの予測 - エンドユーザー別

  • 市場収益シェア（%）、2022年および2030年
  • 病院・診療所
  • 外来手術センター

第10章 北米のグリオーマ治療市場：国別分析

  • 米国
  • カナダ
  • メキシコ

第11章 北米のグリオーマ治療市場：業界情勢

  • 市場参入企業の成長戦略（%）
  • 有機的展開
  • 無機的開発

第12章 企業プロファイル

  • F. Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals LLC
  • Merck & Co Inc
  • Sun Pharmaceutical Industries Ltd
  • Amgen Inc
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Amneal Pharmaceuticals Inc
  • Karyopharm Therapeutics Inc
  • Biocon Ltd

第13章 付録

図表

List Of Tables

  • Table 1. North America Glioma Treatment Market Segmentation
  • Table 2. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 3. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 4. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 5. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 6. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 7. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 8. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 9. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 10. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 11. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 12. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 13. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 14. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 15. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 16. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 17. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 18. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 19. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 20. Organic Developments Done By Companies
  • Table 21. Inorganic Developments Done By Companies
  • Table 22. Glossary of Terms, North America glioma treatment market

List Of Figures

  • Figure 1. North America Glioma Treatment Market Segmentation, By Country
  • Figure 2. North America Glioma Treatment Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. North America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
  • Figure 6. Astrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
  • Figure 10. Surgery: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Chemotherapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Radiation Therapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. North America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
  • Figure 15. Low Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Grade I: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Grade II: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. High Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Grade III: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Grade IV: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. North America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 22. Hospital & Clinics: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Ambulatory Surgical Centers: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. North America Glioma Treatment Market, 2022 ($Mn)
  • Figure 25. North America Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
  • Figure 26. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 27. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 29. Growth Strategies Done by the Companies in the Market, (%)
目次
Product Code: BMIRE00029270

The North America glioma treatment market is expected to grow from US$ 2,179.88 million in 2022 to US$ 4,377.38 million by 2030. It is estimated to grow at a CAGR of 9.1% from 2022 to 2030.

Initiatives by Regional and State Governments to Provide Patients Access to Treatment Fuels North America Glioma Treatment Market

In December 2021, the Patient Access Network (PAN) Foundation and the American Brain Tumor Association announced a new partnership to support persons with glioblastoma by offering financial assistance for services worth up to US$ 1,600 per year for patients. Moreover, leading companies in the North America glioma treatment market focus on launching new products and developing existing ones. In December 2020, CNS Pharmaceuticals, Inc. announced the authorization of the use of berubicin by the Food and Medication Administration to treat patients with glioblastoma multiforme. In addition, the Food and Medication Administration designated LP-184 by Lantern Pharma Inc. as an orphan medication in August 2021 for treating glioblastoma multiforme and other malignant gliomas. A webinar on glioblastoma multiforme (GBM) and the potential of Lantern Pharma\'s LP-184 for treating GBM and other types of brain cancer was also held in May 2020. Thus, efforts made by regional and state governments to provide patients with access to novel treatments accelerate the North America glioma treatment market growth.

North America Glioma Treatment Market Overview

The North America glioma treatment market in North America is segmented into the US, Canada, and Mexico; the US holds the largest share of the market in this region. The market growth is mainly attributed to the increasing brain tumor cases, rapid technological innovations, and developing healthcare infrastructure. According to a report published by the National Brain Tumor Society in 2023, glioblastoma is one of the deadliest, most complex, and treatment-resistant forms of cancer. Over 14,490 Americans are projected to receive a GBM diagnosis in 2023, accounting for ~50.1% of all primary malignant brain tumors. Prominent players in the North American market are focusing on various growth strategies such as mergers, acquisitions, partnerships, and new product launches to expand their geographic presence and enhance their product offerings. For instance, Elekta, a Sweden-based company, collaborated with GE Healthcare to bring innovations in the field of radiation oncology. Through this collaboration, hospitals would be provided with a wide range of treatments for cancer patients requiring radiation therapy.

The US holds a significant share of the North America glioma treatment market in North America. The market growth in this country is primarily driven by the increasing prevalence of brain tumor, growing technological advancements in glioma treatment, and the rising number of smokers. According to the American Society of Clinical Oncology (ASCO), in 2022, nearly 24,530 adults (13,840 men and 10,690 women) are estimated to be diagnosed with primary cancerous tumors of the brain and spinal cord in the US. Brain tumors are the primary central nervous system (CNS) malignancies, which account for 85-90% of all primary CNS cases. The demand for faster treatment is growing with the rising number of brain tumor cases. According to the Brain Tumor Registry of Canada, 4 out of 100,000 people in Canada suffer from glioblastoma, and nearly 1,000 Canadians are diagnosed with glioblastoma each year. The glioblastoma treatment market players are adopting various organic and inorganic strategies to succeed in the Canadian market. In February 2021, Medexus Pharmaceuticals Inc. initiated the commercial launch of Gleolan in Canada, which was previously only distributed under the Health Canada special access program. Gleolan is an imaging agent that causes high-grade gliomas (malignant and rapidly progressing brain tumors) to fluoresce under blue light, helping neurosurgeons better visualize these gliomas for complete removal. There are currently no other approved optical imaging agents in Canada for visualizing malignant tissues during glioma surgery. Further, developing healthcare infrastructure, increasing investments in research & development, and improvements in treatment procedures are anticipated to drive the North America glioma treatment market in Mexico during the forecast period.

North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Glioma Treatment Market Segmentation

The North America glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the North America glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the North America glioma treatment market in 2022.

Based on treatment type, the North America glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the North America glioma treatment market in 2022.

Based on grade, the North America glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the North America glioma treatment market in 2022.

Based on end user, the North America glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the North America glioma treatment market in 2022.

Based on country, the North America glioma treatment market is segmented into Germany, the US, Canada, and Mexico. The US dominated the North America glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the North America glioma treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Glioma Treatment Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Initiatives by Regional and State Governments to Provide Patients Access to Treatment
    • 4.1.2 Increase in Prevalence of High-Grade Glioma
  • 4.2 Key Market Restraints
    • 4.2.1 High Cost of Diagnosis
  • 4.3 Key Market Opportunities
    • 4.3.1 Advancements in Healthcare Sector
  • 4.4 Future Trends
    • 4.4.1 Surge in Drug Approvals for Glioma Treatment
  • 4.5 Impact Analysis:

5. Glioma Treatment Market - North America Market Analysis

  • 5.1 North America Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

  • 6.1 Overview
  • 6.2 North America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
  • 6.3 Astrocytoma
    • 6.3.1 Overview
    • 6.3.2 Astrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Oligoastrocytoma
    • 6.4.1 Overview
    • 6.4.2 Oligoastrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Oligodendroglioma
    • 6.5.1 Overview
    • 6.5.2 Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

  • 7.1 Overview
  • 7.2 North America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
  • 7.3 Surgery
    • 7.3.1 Overview
    • 7.3.2 Surgery: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Chemotherapy
    • 7.4.1 Overview
    • 7.4.2 Chemotherapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Radiation Therapy
    • 7.5.1 Overview
    • 7.5.2 Radiation Therapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

  • 8.1 Overview
  • 8.2 North America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
  • 8.3 Low Grade
    • 8.3.1 Overview
    • 8.3.2 Low Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.2.1 Grade I: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.2.2 Grade II: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 High Grade
    • 8.4.1 Overview
    • 8.4.2 High Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.4.2.1 Grade III: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.4.2.2 Grade IV: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 North America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Hospital & Clinics
    • 9.3.1 Overview
    • 9.3.2 Hospital & Clinics: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Ambulatory Surgical Centers
    • 9.4.1 Overview
    • 9.4.2 Ambulatory Surgical Centers: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Glioma Treatment Market - Country Analysis

  • 10.1 Overview
    • 10.1.1 North America Glioma Treatment Market, by Country
      • 10.1.1.1 US
        • 10.1.1.1.1 US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.1.2 US: North America Glioma Treatment Market, by Disease
        • 10.1.1.1.3 US: North America Glioma Treatment Market, by Treatment Type
        • 10.1.1.1.4 US: North America Glioma Treatment Market, by Grade
        • 10.1.1.1.4.1 US: North America Glioma Treatment Market, by Low Grade
        • 10.1.1.1.4.2 US: North America Glioma Treatment Market, by High Grade
        • 10.1.1.1.5 US: North America Glioma Treatment Market, by End User
      • 10.1.1.2 Canada
        • 10.1.1.2.1 Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.2.2 Canada: North America Glioma Treatment Market, by Disease
        • 10.1.1.2.3 Canada: North America Glioma Treatment Market, by Treatment Type
        • 10.1.1.2.4 Canada: North America Glioma Treatment Market, by Grade
        • 10.1.1.2.4.1 Canada: North America Glioma Treatment Market, by Low Grade
        • 10.1.1.2.4.2 Canada: North America Glioma Treatment Market, by High Grade
        • 10.1.1.2.5 Canada: North America Glioma Treatment Market, by End User
      • 10.1.1.3 Mexico
        • 10.1.1.3.1 Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.3.2 Mexico: North America Glioma Treatment Market, by Disease
        • 10.1.1.3.3 Mexico: North America Glioma Treatment Market, by Treatment Type
        • 10.1.1.3.4 Mexico: North America Glioma Treatment Market, by Grade
        • 10.1.1.3.4.1 Mexico: North America Glioma Treatment Market, by Low Grade
        • 10.1.1.3.4.2 Mexico: North America Glioma Treatment Market, by High Grade
        • 10.1.1.3.5 Mexico: North America Glioma Treatment Market, by End User

11. North America Glioma Treatment Market Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies Done by the Companies in the Market, (%)
  • 11.3 Organic Developments
    • 11.3.1 Overview
  • 11.4 Inorganic Developments
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 F. Hoffmann-La Roche Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Arbor Pharmaceuticals LLC
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Merck & Co Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Sun Pharmaceutical Industries Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Amgen Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Teva Pharmaceutical Industries Ltd
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Pfizer Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Amneal Pharmaceuticals Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Karyopharm Therapeutics Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Biocon Ltd
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms